摘要
目的分析探究重组人血小板生成素对特发性血小板性紫癜的疗效和安全性评价。方法选取2015年3月—2016年1月在该科室确诊并决定接受治疗的特发性血小板减少性紫癜患者,按照病历号的不同,单号为观察组给予重组人血小板生成素加达那唑治疗。双号为对照组只给予达那唑治疗。观察两组患者治疗的有效率,不良反应发生率及治疗后血小板恢复情况。结果两组患者治疗后观察组治疗的有效率(62.22%)明显高于对照组患者(33.33%),差异有统计学意义(χ~2=7.215,P<0.05)。两组患者经两种方法治疗后,观察组经重组人促血小板生成素加达那唑治疗后不良反应发生率(11.11%)低于经达那唑治疗的对照组不良反应发生率(35.56%),差异有统计学意义(χ~2=6.354,P<0.05)。对出院的患者进行为期1年的随访,主要复查血象,骨髓象。了解患者血小板的功能状态,及患者有无不适症状。观察组患者只有2例,发现血小板计数减少,造血功能异常。对照组有7例发生不良反应,病情复发。3例病情较之前加重,差异有统计学意义(P<0.05)。结论经重组人促血小板生成素治疗的患者血小板恢复情况较好,不良反应发生率较低,效果显著,安全可靠,值得在临床上进行推广。
Objective To analyze the evaluation on curative effect and safety of recombinant human TPO in the idiopathic thrombocytopenic purpura. Methods The patients with idiopathic thrombocytopenic purpura diagnosed and treated in our department from March 15, 2015 to January 10, 2016 were selected and divided into two groups according to the admission order, the observation group were treated with recombinant human TPO and danazol, while the control group were only treated with danazol, and the treatment effective rate, incidence rate of adverse reactions and recovery situation of platelet after treatment of the two groups were observed. Results After treatment, the treatment effective rate in the observation group was obviously higher than that in the control group（62.22% vs 33.33%）, and the difference was obvious, with statistical significance（χ^2=7.215, P〈0.05）, after treatment, the incidence rate of adverse reactions was lower than that in the control group（11.11% vs 35.56%）, and the difference was obvious, with statistical significance（χ^2=6.354, P 0.05）, and the discharged patients were followed up for one year, and the hemogram and myelogram were mainly reexamined, to know the functional state of platelets and whether the patients were discomforted or not, and in the observation group, only two patients had thrombocytopenia and abnormal hemopoiesis, and in the control group, 7 cases had adverse reactions and the diseases of 3 cases were more serious, and the differences were obvious, with statistical significance（P〈0.05）. Conclusion The platelet recovery situation of recombinant human TPO is better, with low incidence rate of adverse reactions and obvious effect, and it is safe and reliable, which is worth promotion in clinic.
作者
陶刚
李晓燕
潘琳
李家丛
TAO Gang;LI Xiao-yan;PAN Lin;LI Jia-cong(Department of Blood Donation Service, Baoshan Blood Center, Baoshan, Yunnan Province, 678000 China;Department of Oneology, Baoshan People＇ s Hospital, Baoshan, Yunnan Province, 678000 China)
出处
《系统医学》
2018年第1期55-57,共3页
Systems Medicine
